Using Torque Teno Virus levels to predict treatment response in lung cancer patients
Official title: Efficacy of Torque Teno Virus as a Biomarker for Predicting Treatment Response of Immune Checkpoint Inhibitor Therapy and Postoperative Outcome in NSCLC Patients - A Prospective Non-interventional Single-arm Study
Run by Medical University of Vienna · NCT06967532 · Data updated 2026-11-12
This study is testing if measuring Torque Teno Virus levels in the blood can help predict how well lung cancer patients respond to a specific type of treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | Medical University of Vienna Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Vienna) |
| Status | Recruiting |
| Started | September 6, 2024 |
| Main results expected | September 2026 |
| Study ends | September 2026 |
| Registry record updated | May 13, 2025 |
| Trial ID | NCT06967532 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients with histologically or cytologically verified stage II-IV NSCLC who are operable after neoadjuvant systemic therapy involving immune checkpoint inhibitors.
✕Probably not a fit
Patients with early-stage NSCLC or those not receiving immune checkpoint inhibitors may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the potential of Torque Teno Virus (TTV) levels as a biomarker to predict treatment responses in patients with non-small cell lung cancer (NSCLC) undergoing immune checkpoint inhibitor therapy. By analyzing blood samples, the study aims to establish a correlation between TTV levels and patient outcomes, including treatment efficacy and postoperative complications. The research seeks to improve the management of NSCLC patients by providing a more reliable method for assessing treatment response compared to current imaging techniques, which can be misleading.
Why it matters
Potential benefit: If successful, this study could lead to more personalized treatment strategies for NSCLC patients, improving their chances of successful outcomes.
How similar studies have gone: While the use of TTV as a biomarker is being explored in other contexts, its application in oncology, particularly for NSCLC and immune checkpoint inhibitors, is relatively novel and untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- Histologically or cytologically verified NSCLC stage II-IV (OMD) according to UICC TNM8 edition considered operable in curative intent after neoadjuvant systemic therapy containing immune checkpoint inhibition by local multidisciplinary tumor board (MDT) decision. ECOG \< or = 1 Staging with PET/CT and cMRI/CCT Written informed consent Exclusion Criteria: \-
Where it's running
-
Medical University of Vienna
Vienna, Austria Recruiting
Study contacts
- Study coordinator: Clemens Aigner, MD, MBA, FETCS
- Email: clemens.aigner@meduniwien.ac.at
- Phone: +43140400
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Investigating KQB365 for treating advanced solid tumors
This study tests if a new treatment called KQB365, alone or with another drug, can help adults with advanced solid tumors that have specific genetic mutations.
-
TS-104: a first-in-human, dose-escalation study for advanced solid tumors
This study tests TS-104, a peptide-drug conjugate, as a single therapy in adults with advanced solid tumors like NSCLC, HNSCC, esophageal, gastric, ovarian, or endometrial cancer to see if it is safe and tolerable and whether it shows any benefit.
-
Icotinib after surgery for early EGFR-mutant NSCLC
This study tests whether giving icotinib after surgery helps patients with early-stage EGFR-mutant NSCLC compare to just following them after surgery.
-
Oral Paclitaxel with Immunotherapy and SBRT as Neoadjuvant Treatment for Older Adults with NSCLC
This trial tests a new, lighter neoadjuvant therapy that combines an oral paclitaxel solution, an immune checkpoint inhibitor, and SBRT for adults aged 70 and older with resectable NSCLC to see if it can shrink tumors before surgery.
-
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant NSCLC
This trial tests a targeted induction approach using fumetinib with platinum-based chemotherapy and concurrent radiochemotherapy in adults with unresectable stage III EGFR-mutant NSCLC to see if this combo can improve outcomes before possible surgery.
-
Pralsetinib Drug Interaction Study in RET Fusion/MUTATION Positive Solid Tumors
This trial tests whether pralsetinib changes how the body processes certain medicines in adults with RET fusion- or mutation-positive advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.